UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000048498 |
|---|---|
| Receipt number | R000055223 |
| Scientific Title | Proteomics and pathological analysis of human brain samples |
| Date of disclosure of the study information | 2022/07/31 |
| Last modified on | 2023/02/03 13:29:12 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Proteomics and pathological analysis of human brain samples
Acronym
Proteomics
Scientific Title
Proteomics and pathological analysis of human brain samples
Scientific Title:Acronym
Proteomics and pathological analysis
Region
| Japan |
Condition
Condition
Alzheimer's disease, tauopathy, Neurodegenerative disorders
Classification by specialty
| Neurology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We will conduct proteomic analysis, histopathological examination, and development and evaluation of molecular markers to visualize astrocyte function in human brain tissue.
Basic objectives2
Others
Basic objectives -Others
To explore the molecular mechanisms that influence astrocyte dysfunction associated with dementia pathology and to identify astrocyte functional molecules that are linked to the onset of dementia.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Identification of variable protein groups in human brain diseases by proteome analysis, and their expression profiles. Quantitative and spatial expression distribution of variable protein groups by histopathology. The amount and distribution of binding sites of radiolabeled drugs as candidate molecular markers by autoradiography.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 90 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Pathological diagnosis
Key exclusion criteria
Fulfill pathological diagnoses other than those of the diseases covered in the current study.
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | Yuhei |
| Middle name | |
| Last name | Takado |
Organization
National Institutes for Quantum Science and Technology
Division name
Institute for Quantum Medical Science
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku
TEL
0432063251
takado.yuhei@qst.go.jp
Public contact
Name of contact person
| 1st name | Yuhei |
| Middle name | |
| Last name | Takado |
Organization
National Institutes for Quantum Science and Technology
Division name
Institute for Quantum Medical Science
Zip code
263-8555
Address
4-9-1 Anagawa, Inage-ku
TEL
0432063251
Homepage URL
takado.yuhei@qst.go.jp
Sponsor or person
Institute
National Institutes for Quantum Science and Technology
Institute
Department
Personal name
Funding Source
Organization
Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Institutes for Quantum Science and Technology
Address
4-9-1 Anagawa, Inage-ku
Tel
043-206-4706
helsinki@qst.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 07 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2022 | Year | 07 | Month | 13 | Day |
Date of IRB
| 2022 | Year | 07 | Month | 14 | Day |
Anticipated trial start date
| 2022 | Year | 08 | Month | 15 | Day |
Last follow-up date
| 2027 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
NA
Management information
Registered date
| 2022 | Year | 07 | Month | 28 | Day |
Last modified on
| 2023 | Year | 02 | Month | 03 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055223
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
